Genomics of Drug Resistance
In session VII of Myeloma2018, the underlying genomics and proteomics of drug resistance in MM are investigated. Arun Wiita, MD, PhD, Brian Van Ness, PhD, Marc Raab, MD, Mike Chapman, PhD, Florian Bassermann, MD, PhD, and Anja Seckinger, MD, discuss the resistance of various proteasome inhibitors and immunomodulatory drugs, with reference to bone marrow signaling mechanisms, plasma cell tumor sensitivities, and driver gene mutations.
University of California, San Francisco, CA
Arun Wiita, MD, PhD, from the University of California, San Francisco, CA, discusses the proteomics of drug resistance.
University of Minnesota, Minneapolis, MN
Brian Van Ness, PhD, from the University of Minnesota, Minneapolis, MN, speaks about proteasome inhibitor resistance.
University of Heidelberg, Heidelberg, Germany
Marc Raab, MD, from the University of Heidelberg, Heidelberg, Germany, speaks about the genetic analysis of refractory multiple myeloma.
University of Cambridge, Cambridge, UK
Mike Chapman, PhD, from the University of Cambridge, Cambridge, UK, explores the signatures of drug resistance.
Technical University of Munich, Munich, Germany
Florian Bassermann, MD, PhD, from the Technical University of Munich, Munich, Germany, discusses IMiD resistance and metabolism.
University of Heidelberg, Heidelberg, Germany
Anja Seckinger, MD, from the University of Heidelberg, Heidelberg, Germany, presents interesting information for CD38 sensitivity and resistance.